ABSTRACT
Se diseñó un estudio de Farmacovigilancia (FVG), centrado en tres Hospitales Públicos de Córdoba, buscando detectar Reacciones Adversas por medicamentos. A tal fin se realizaron cursos formadores de recursos humanos en FVG. Se distribuyeron fichas de FVG., de diseño propio, recuperadas luego. Para cálculo estadístico se aplicó el INFO 4. Se recuperaron 84 fichas informadas Los grupos de medicamentos involucrados: fueron: Antibióticos (22%), cardiovasculares (16%), antiulcerosos (10%), ansiolíticos (8.75%), AINEs (8%), oncológicos (6%), anticonvulsivantes (3.75%), hipolipemiantes (3.5%), hormonas sexuales (2.5%), hipoglucemiantes (2.5%), expansores plasmáticos (2.5%). Los órganos afectados por RAM fueron: SNC (25%), piel (25%), gastrointestinal (17.5%), Sangre (7.5%), cardiovascular (7.5%), respiratorio (7%), inmunes (6%), renal (4%). El análisis de imputabilidad indicó: RAM Definidas: 10% - RAM Probables: 90%.
There were designed Monitorings study (FVG), centred on three Public Hospitals of C6rdoba, seeking to detect Adverse Reactions for medicines. To such purpose there were realized forming courses of human resources in FVG. FVG's cards were distributed, of own design, recovered then. For statistical calculation there was applied the INFO 4. 84 informed cards were recovered. The groups of involved medicines: they were: Antibiotics (22%), cardiovascular (16%), antiulcerous (10%), anxiolytics (8.75%), nonsteroidal anti-inflammatory (8%), onchologics (6%), anticonvulsants (3.75%), hypolypemics (3.5%), sexual hormones (2.5%), hypoglycemics (2.5%), plasmatic expansors (2.5%). The organs affected by RAM were: Central Nervous System (25%), skin (25%), gastrointestinal (17.5%), Bleeds (7.5%), cardiovascular (7.5%), respiratory (7%), immune (6%), renal (4%). The analysis of imputability indicated: Definite RAM: 10 % Probable RAM: 90%.
Subject(s)
Humans , Drug Monitoring , Pharmaceutical Preparations/adverse effects , Adverse Drug Reaction Reporting Systems , ArgentinaABSTRACT
El estudio tuvo un año de duración. Se evaluó la eficacia terapéutica de un compuesto a base de un gel de hidróxido de bismuto coloidal al 3% con pectina (Crema de Bismuto Chobet) en la diarrea aguda del lactante. El estudio se realizó en 48 lactantes afectados de diarrea aguda de menos de 24 horas de evolución. La investigación utilizó metodología a doble ciego, fue randomizada y controlada con placebo. Ambos grupos de tratamiento fueron similares en cuanto a características demográficas y etiopatogénicas. El porcentaje de niños mejorados clínicamente a las 24 horas de tratamiento y la reducción del número de deposiciones fue del 45,8% en el grupo placebo y del 83,4% en el grupo tratado con la Crema de Bismuto (pSubject(s)
Infant
, Child
, Bismuth/therapeutic use
, Diarrhea
, Gastroenteritis
, Pectins/therapeutic use
, Data Interpretation, Statistical
, Double-Blind Method
, Placebos
ABSTRACT
Two groups of patients were studied, both in accordance with ACR criteria. First group (41 cases) suffering R.A.. Second group (36 cases) suffering O.A. In both pathologies MMPs, ICAM and VCAM from synovial fluid and plasma were studied. Measurements were made with ELISA-sandwich in a Metrolab spectrophotometer at 410 mm for MMPs, and 491 nm for ICAM and VCAM. As control, samples of patients with noninflammatory muscle skeletal disorders or traumatic arthritis and healthy witness were used. Synovial concentration of MMPs in R.A. was 1402+76 ng/ml, a higher significant value (p<0.0001) compared with ostheoarthritis: 353+23 ng/ml. In the witness plasma, MMPs were not detected. Plasmatic and synovial levels of the adhesion molecules present different values in both pathologies and between them. Synovial ICAM level in R.A. (280+9.8 ng/ml) is significantly higher than in O.A. (163+10 ng/ml) (p<0.001), but lower than plasmatic ones (370+35 ng/ml) (p,0.001). All these values are significantly higher than the normal plasma (121+6.5 ng/ml) (p<0.005, and p<0.0001, respectively) VCAM increase regarding basal values (140+5.6 ng/ml) (p<0.001) and in a similar proportion for both pathologies (R.A.: 186+9.3 ng/ml and O.A.: 207+14.3 ng/ml). Their plasmatic levels were higher (270+45 and 320+38 ng/ml) (p<0.001) but without significative difference between them. There is correlation among MMPs, ICAM and VCAM variations. The variability can be explained by concomitance several evolutive steps. Each pathology shows a different grade of cellularity, inverted predominance in the relation TIMPs/collagenase and different generator mechanisms of MMPs. Our findings reinforce the importance as diagnostic guide of adhesion molecules dosage, and possible therapeutic use of MMPs inhibitors and ICAM ou VCAM antagonists en R.A. and related pathologies.